Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.

Abstract

Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly-targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti-angiogenic therapy with specifically-targeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of alpha(nu)beta(3)-targeted anti-angiogenic perfluorocarbon nanoparticles in (1) the detection of molecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image-based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy.

• Authors: Shelton D Caruthers, Tillmann Cyrus, Patrick M Winter, Samuel A Wickline, Gregory M Lanza
• Journal: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology (Wiley Interdiscip Rev Nanomed Nanobiotechnol) 2009 May-Jun Vol. 1 Issue 3 Pg. 311-23 ISSN: 1939-0041 [Electronic] United States
• PMID: 20049799 (Publication Type: Journal Article, Review)
• Copyright: 2009 John Wiley & Sons, Inc.

Chemical References

• Angiogenesis Inhibitors
• Drug Carriers
• Fluorocarbons

Topics

• Angiogenesis Inhibitors (administration & dosage, chemistry)
• Animals
• Atherosclerosis (diagnosis, drug therapy)
• Diagnostic Imaging (methods)
• Drug Carriers (chemistry)
• Fluorocarbons (chemistry)
• Humans
• Molecular Probe Techniques
• Nanoparticles (chemistry, therapeutic use)